KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that its scientists are presenting research data at two scientific conferences. These oral presentations highlight Trevena’s research demonstrating that ligand bias at the angiotensin II type I receptor (AT1R) translates into differentiable and beneficial cardiovascular pharmacology in vivo. The first presentation took place at the Gordon Research Conference: Phosphorylation & G-Protein Mediated Signaling Networks held June 6-11, 2010 at the University of New England in Biddeford, Maine, where Jonathan Violin, Ph.D., Trevena’s Head of Biology, presented on June 9 at 8:10 p.m. ET. The second presentation will be given at the 9th Annual World Pharmaceutical Congress being held June 15-17, 2010 at the Sheraton Philadelphia City Center in Philadelphia, Pennsylvania, where Scott DeWire, Ph.D., Senior Research Scientist at Trevena, will present on June 17 at 9:30 a.m. ET.
